Genetic activity profiles of anticancer drugs

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 355, Issue 1-2, 1996, Pages 171-208

  Jackson, Marcus A ^a   Stack, H Frank ^a   Waters, Michael D ^b  

^a INTEGRATED LABORATORY SYSTEMS   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

anticancer drug; genetic activity profile

Indexed keywords

AMSACRINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; AZACITIDINE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DIETHYLSTILBESTROL; DOXORUBICIN; ETHINYLESTRADIOL; ETOPOSIDE; FLUOROURACIL; GYRASE INHIBITOR; HYDROXYUREA; LOMUSTINE; MEGESTROL ACETATE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; THIOTEPA; UNINDEXED DRUG; VINCRISTINE;

GENOTOXICITY; HUMAN; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030591660     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/0027-5107(96)00028-0     Document Type: Article

References (79)

1. Adair FE, Bagg HJ (1931) Experimental and clinical studies on the treatment of cancer by dichloroethyl sulfide (mustard gas). Ann Surg 93:190.
2. Allen JW, Ehling UH, Moore MM, Lewis SE (1995) Germ-line specific factors in chemical mutagenesis. Mutation Res 330:219-232.
3. Ames BN, McCann J, Yamasaki E (1975) Method for detecting carciogens and mutagens with the Salmonella/mammalian microsome test. Mutation Res 31:347-364.
4. Anderson D, Bishop JB, Garner RC. Ostrosky-Wegman P, Selby PB (1995) Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutation Res 330:115-182.
5. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Poli C, Spalla C (1969) Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caeciu. Biotech Bioeng 11:1101.
6. Ashby J, deSerres FJ, Draper MH, Ishidate M, Margolin B, Matter BE, Shelby M (eds) (1985) Evaluation of Short-Term Tests for Carcinogens, Progress in Mutation Research, vol 5. Elsevier, New York, 752 pp.
7. Ashby J, Tennant RW (1991) Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutation Res 257:229-306.
8. Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet ii:104.
9. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB (1979) The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. New Eng J Med 301:743-748.
10. Bodmer W, McKie R (1994) The Book of Man. Little Brown, London.
11. Dao TL, Huggins C (1955) Bilateral adrenalectomy in the treatment of cancer of the breast. AMA Arch Surg 71:645.
12. De Gramont A, Rioux E, Drolet Y, Delage JM (1985) Erythrocyte mean corpuscular volume during cytostatic therapy and the risk of secondary leukemia. Br J Cancer 55:493-495.
13. Dellarco VL, Erickson RP, Lewis SE, Shelby MD (1995) Mutagenesis and human genetic disease: and introduction. Environ Mol Mutagen 25 (Suppl. 26):2-6.
14. Einhorn N (1978) Acute leukemia after chemotherapy (melphalan). Br J Cancer 41:444-447.
15. Elion GB, Burgi E, Hitchings GH (1952) Studies on condensed pyrimidine synthesis: IX. The synthesis of some 6-substituted purines. J Am Chem Soc 74:411.
16. Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussof B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hayes DM, Blom J, Leone LA, Haurani F, Kyle R, Hutchinson JL, Forcier RJ, Moon JH (1968) Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32:507.
17. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). New Eng J Med 238:787.
18. Farmer PB (1987) Metabolism and reactions of alkylating agents. Pharmacol Ther 35:301.
19. Favor J (1995) Mutagenesis and human genetic disease: dominant mutation frequencies and a characterization of mutational events in mice and humans. Environ Mol Mutagen 25 (Suppl 26):81-87.
20. Frank W, Osterberg AE (1960) Mitomycin C (NSC-26980) - an evaluation of the Japanese reports. Cancer Chemother Rep 9:114.
21. Ferguson LR, Baguley BC (1994) Topoisomerase II enzymes and mutagenicity. Environ Mol Mutagen 24:245-261.
22. Furr BJA, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Therapeut 25:127.
23. Garrett NE, Stack HF, Waters MD (1986) Evaluation of the genetic activity profiles of 65 pesticides. Mutation Res 168:301-325.
24. Oilman A, Philips FS (1946) The biological actions and therapeutic applications of B-chloroethyl amines and sulfides. Science 103:409.
25. Greene MH, Boice JD, Greer BE, Blessing JA, Dembo AJ (1982) Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer. New Eng J Med 307:1416-1421.
26. Haas JF, Kittelmann B, Mehnert WH, Staneczek W, Mohner M, Kaldor JM, Day NE (1987) Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer 55:213-218.
27. Haseman JK, Zeiger E, Shelby MD, Margolin BH, Tennant RW (1990) Predicting rodent carcinogenicity from four in vitro genetic toxicity assays: an evaluation of 114 chemicals studied by the National Toxicology Program. J Am Stat Assoc 85:964-971.
28. Heidelberger C (1965) Fluorinated pyrimidines. In: Davidson JN, Cohn WE (eds) Progress in Nucleic Acid Research and Molecular Biology. Academic Press. New York, pp. 1-50.
29. IARC (1987) IARC Monographs on the evaluation of carcinogenic risks to humans: genetic and related effects: an update of selected IARC Monographs from Vols. 1 to 42, Suppl. 6. International Agency for Research on Cancer, Lyon, France, 440 pp.
30. IARC (1990) IARC Mongraphs on the evaluation of carcinogenic risk to humans, Vol. 50, Pharmaceutical drugs. International Agency for Research on Cancer, Lyon, France, 415 pp..
31. IARC (1992) IARC Monographs on the evaluation of carcinogenic risks to humans, Vol. 53, Occupational exposures in insecticide application and some pesticides. International Agency for Research on Cancer, Lyon. France, 612 pp..
32. Jackson RC, Harkrader RJ (1981) The contribution of de novo and salvage pathways of nucleotide biosynthesis in normal and malignant cells. In: Tattersall MHN, Fox RM (eds) Nucleosides and Cancer Treatment. Academic Press, Sydney, pp. 18-31.
33. Johnson RK, Zee-Cheng RK-Y, Lee WW, Acton EM, Henry DW, Cheng CC (1979) Experimental antitumor activity of aminoanthraquinones. Cancer Treat Rep 63:425-439.
34. Krause JR, Ayuyang HQ, Ellis LD (1985) Secondary non-hematopoietic cancers arising following treatment of hematopoietic disorders. Br J Cancer 55:512-515.
35. Lerner LJ, Jordan VC (1990) Development ot antiestrogens and their use in breast cancer: Eighth Cain Memorial Awards Lecture. Cancer Res 50:4177.
36. Levine E (1992) Transitional cell carcinoma of the renal pelvis associated with cyclophosphamide therapy. Am J Roentgenol 159:1027-1028.
37. Lissauer (1865) II. Zwei Fälle von Leukaemie. Berl Klin 40:403.
38. Lovell DP (1995) Population genetics of induced mutations. Environ Mol Mutagen 25 (Suppl 26): 65-73.
39. Meer L, Janzer RC, Kleihues P, Kolar GF (1986) In vivo metabolism and reaction with DNA of the cytostatic agent 5,(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). Biochemistry 35:3243.
40. Merkel DC, Osborne CK (1988) Steroid receptors in relation to response. In: Stoll BA (ed) Endocrine Management of Cancer: I. Biological Bases. S. Karger, Basel, pp. 84-99.
41. Murdock KC, Child RG, Fabio PF, Angier RB, Wallace RE, Durr EE, Citarella RV (1979) Antitumor agents I, 1,4-bis[(aminoalkyl)amino]-9,10-anthracenediones. J Med Chem 22:1024-1030.
42. Olshan AF (1995) Lessons learned from epidemiologic studies of environmental exposure and genetic disease. Environ Mol Mutagen 25 (Suppl 26):74-80.
43. Pearson OH, Ray BS (1959) Results of treatment of metastatic mammary carcinoma. Br J Cancer 12:85.
44. Pedersen-Bjergaard J, Ersboll J, Hansen VL, Sorensen BL, Christoffersen K, Hou-Jensen K, Nissen NI, Knudsen JB, Hansen MM (1988) Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma, New Eng J Med 381:1028-1032.
45. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, Keiding N, Larsen SO, Philip P, Larsen MS, Schultz H, Nissen NI (1985) Risk of acute nonlymphocytic leukemia and preleukemia in patients teated with cyclophosphamide for non-Hodgkin's lymphomas: comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 103:192-200.
46. Penn I (1986) Malignancies induced by drug therapy: a review. IARC Sci Publ No 78:13-27.
47. Perez CA, Fair WR, Ihde DC (1989) Carcinoma of the prostate. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer Principles and Practice of Oncology. JB Lippincott Co., Philadelphia, pp. 1023-1058..
48. Petering DH, Byrnes RW, Antholine WE (1990) The role of redox-active metals in the mechanism of action of bleomycin. Chem-Biol Interact 73:133-182.
49. Portugal MA, Falkson HC, Stevens K, Falkson G (1979) Acute leukemia as a complication of long-term treatment of advanced breast cancer. Cancer Treat Rep 63:177-181.
50. Povirk LF, Finley Austin MJ (1991) Genotoxicity of bleomycin. Mutation Res 257:127-143.
51. Pratt CB, Pui C-H (1991) Second tumors after treatment with anticacer drugs. In: Powis G, Hacker MP (eds) The Toxicity of Anticancer Drugs. Pergamon Press, New York, pp. 28-43.
52. Pratt WB, Ruddon RW, Ensminger WD, Maybaum J (1994) The Anticancer Drugs, 2nd edn. Oxford University Press, New York, 352 pp.
53. Prough RA, Tweedie DJ (1987) Procarbazine. In: Powis G, Prough RH (eds) Metabolism and Action of Anticancer Drugs. Taylor and Francis, London, pp. 29-47.
54. Reed DJ, May HE, Boose RB, Gregory KM, Beilstein MA (1975) 2-Chloroethanol formation as evidence for a 2-chloroethyl alkylating intermediate during chemical degradation of 1,(2-chloroethyl)-3-cyclohexyl-1-nitrosourea and 1,(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. Cancer Res 35:568.
55. Rice JA, Crothers DM, Pinto AL, Lippard SJ (1988) The major adduct of the antitumor drug cis-diaminedichloroplatinum(II) with DNA bends the duplex by ∼ 40° toward the major groove. Proc Natl Acad Sci USA 85:4158.
56. Roberts JJ, Brent TP, Crathorn AR (1971) Evidence for the inactivation and repair of the mammalian DNA template after alkylation by mustard gas and half mustard gas. Eur J Cancer 7:515.
57. Ruddon RW, Johnson JM (1968) The effects of nitrogen mustard on DNA template activity in purified DNA and RNA polymerase systems. Mol Pharmacol 4:258..
58. Russell LB, Hunsicker PR, Cachesro NLA, Bangham JW, Russell WL, Shelby MD (1989) Chlorambucil effectively induces deletion mutations in mouse germ cells. Proc Natl Acad Sci. (USA) 86:3704-3708.
59. Russell LB, Hunsicker PR, Shelby MD (1992) Melphalan, a second chemical for which specific-locus mutation induction in the mouse is maximum in early spermatids. Mutation Res 282:151-158.
60. Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci (USA) 77:1561.
61. Schmahl D (1986) Carcinogenicity of anticancer drugs and especially alkylating agents. IARC Sci Publ No 78:29-35.
62. Seeger DR, Cosulich DB, Smith JM, Hultquist ME (1949) Analogs of pteroylglutamic acid. III. 4-Amino derivatives. J Am Chem Soc 71:1753.
63. Seo IS, Clark SA, McGovern FD, Clark DL, Johnson EH (1985) Leiomyosarcoma of the urinary bladder 13 years after cyclophosphamide therapy for Hodgkin's disease. Br J Cancer 55:1597-1603.
64. Spritz R (1994) Molecular genetics of oculocutaneous albinism. Hum Mol Genet 3:1469-1475.
65. Tennant RW, Margolin BH, Shelby MD, Zeiger E, Haseman JK, Spalding J, Caspary W, Resnick M, Stasiewicz S, Anderson B, Minor R (1987) Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Sci 236:933-941.
66. Tewey KM, Chen GL, Nelson EM, Liu LF (1984) Intercalate antitumor drugs interfere with the breakage-reunion reaction of mammalian topoisomerase II. J Biol Chem 259:9182.
67. Tomson AJ (1974) The interactions of platinum compounds with biological molecules, Rec Res Cancer Res 48:38.
68. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J, Gospodarowicz MK, Wacholder S, Inskip PD, Tucker MA, Boice Jr JD (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 87:524-530.
69. Umezawa H, Maeda K, Takeuchi T, Okami Y (1966) New antibiotics, bleomycin A and B. J Antibiot (Tokyo) 19:200.
70. Waters MD, Stack HF, Brady AL, Lohman PHM, Haroun L, Vainio H (1988a) Use of computerized data listings and activity profiles of genetic and related effects in the review of 195 compounds. Mutation Res 205:295-312.
71. Waters MD, Stack HF, Rabinowitz JR, Garrett NE (1988b) Genetic activity profiles and pattern recognition in test battery selection. Mutation Res 205:119-138.
72. Waters MD, Stack HF, Garrett NE, Jackson MA (1991) The genetic activity profile database, Environ Health Perspect 96:41-45.
73. Waters MD, Stack HF, Jackson MA, Bridges BA, Adler I-D (1994) The performance of short-term test in identifying potential germ cell mutagens: a qualitative and quantitative analysis. Mutation Res 341:109-131.
74. Wilkie T (1994) Perilous Knowledge. The Human Genome Project and its Implications. Faber and Faber, London.
75. 3H]vinblastine to embryonic chick brain tubulin and tubulin from sea urchin sperm tail outer doublet microtubules. Biochemistry 14:5586.
76. Wright JA, Chan AK, Choy BK, Hurta RA, McClarty GA, Tagger AY (1990) Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and significance to DNA synthesis. Biochem Cell Biol 68:1364.
77. Zeiger E (1987) Carcinogenicity of mutagens: predictive capability of the Salmonella mutagenesis assay for rodent carcinogenicity. Cancer Res 47:1287-1296.
78. Zeiger E, Haseman JK, Shelby MD, Margolin BH, Tennant RW (1990) Evaluation of four in vitro toxicity tests for predicting rodent carcinogenicity: confirmation of earlier results with 41 additional chemicals. Environ Mol Mutagen 16 (Suppl. 18): 1-14.
79. Zwelling LA, Mayes J, Hinds M, Chan D, Altschuler E, Carroll B, Parker E, Deisseroth K, Radcliffe A, Seligman M (1991) Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions. Biochemistry 30:4048.